News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm (NEOL) as Chief Development Officer



1/7/2011 9:47:47 AM

(BUSINESS WIRE)--INSYS Therapeutics/NeoPharm (Other OTC: NEOL.PK) announces the inclusion of Daniel D. Von Hoff, M.D., F.A.C.P. to their management team as Chief Development Officer. Dr. Von Hoff also currently serves as Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare. He holds an appointment as Clinical Professor of Medicine, University of Arizona, College of Medicine.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES